Literature DB >> 12200779

Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type).

Ole B Suhr1, Bo-Göran Ericzon, Styrbjörn Friman.   

Abstract

Portuguese type familial amyloid polyneuropathy is a dominantly inherited neuropathic amyloidosis caused by a mutant transthyretin (TTR). Because TTR is produced mainly by the liver, liver transplantation (LT) abolishes production of the amyloidogenic variant TTR. To date, the procedure appears to halt the progress of the disease. However, long-term outcome is unknown. The aim of the present study is to evaluate the survival of our initial group of unselected liver transplant recipients with FAP. Seventy patients, 51 transplant recipients and a control group of 19 nontransplantation patients, with disease onset before the age of 55 years were included on the study. Transplant recipients were divided into two categories: (1) early series, with patients followed up for 5 years or longer, and (2) new series, with patients followed up for 1 to 5 years. Nonparametric statistical methods were used. Binary regression analyses were performed by stepwise logistic regression and Cox proportional hazard regression. Survival analysis was performed using Kaplan-Meier analysis, the Cox-Mantel test. Survival analyses and Cox proportional hazard regression analysis were performed from disease onset, not from LT. Significantly decreased survival was noted for transplant recipients with a modified body mass index (mBMI) less than 600 compared with the control group (P < .05). A significant difference in survival also was observed between transplant recipients with an mBMI greater than 600 at the time of LT compared with those with an mBMI less than 600 (P < .02). mBMI and age at LT had a significant impact on survival; whereas late deaths were related to age at LT, early deaths were related to mBMI. The cumulative 10-year survival rate after disease onset was 94% in the new series, with one early death (< 6 months) after LT, compared with a 78% survival rate and eight early deaths in the early series (P = .1).

Entities:  

Mesh:

Year:  2002        PMID: 12200779     DOI: 10.1053/jlts.2002.34386

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  11 in total

1.  Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation.

Authors:  Yoshio Shimojima; Hiroshi Morita; Sachio Kobayashi; Yo-ichi Takei; Shu-ichi Ikeda
Journal:  J Neurol       Date:  2008-05-20       Impact factor: 4.849

2.  Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.

Authors:  Nora S Green; Ted R Foss; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-29       Impact factor: 11.205

3.  Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Authors:  Yuki Ohya; Sadahisa Okamoto; Masayoshi Tasaki; Mitsuharu Ueda; Hirofumi Jono; Konen Obayashi; Kazuhisa Takeda; Hideaki Okajima; Katsuhiro Asonuma; Ryuhei Hara; Hidenobu Tanihara; Yukio Ando; Yukihiro Inomata
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

4.  Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.

Authors:  Giampaolo Merlini; Violaine Planté-Bordeneuve; Daniel P Judge; Hartmut Schmidt; Laura Obici; Stefano Perlini; Jeff Packman; Tara Tripp; Donna R Grogan
Journal:  J Cardiovasc Transl Res       Date:  2013-10-08       Impact factor: 4.132

5.  Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area.

Authors:  Massimo Russo; Luca Gentile; Vincenzo Di Stefano; Gianluca Di Bella; Fabio Minutoli; Antonio Toscano; Filippo Brighina; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-27

6.  Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.

Authors:  Ole B Suhr; Isabel M Conceição; Onur N Karayal; Francine S Mandel; Pedro E Huertas; Bo-Göran Ericzon
Journal:  Neurol Ther       Date:  2014-12-11

7.  Association between Modified Body Mass Index and 30-Day and 1-Year Mortality after Intensive Care Unit Admission: A Retrospective Cohort Study.

Authors:  Tak Kyu Oh; Jaebong Lee; Yeon Joo Lee; Jung-Won Hwang; Sang-Hwan Do; Young-Tae Jeon; In-Ae Song
Journal:  J Clin Med       Date:  2018-04-13       Impact factor: 4.241

Review 8.  Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review.

Authors:  A C Martins; A M Rosa; E Costa; C Tavares; M J Quadrado; J N Murta
Journal:  Biomed Res Int       Date:  2015-10-19       Impact factor: 3.411

9.  Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.

Authors:  Sunil M Kurian; Marta Novais; Thomas Whisenant; Terri Gelbart; Joel N Buxbaum; Jeffery W Kelly; Teresa Coelho; Daniel R Salomon
Journal:  Theranostics       Date:  2016-07-18       Impact factor: 11.556

10.  Value of Preoperative Modified Body Mass Index in Predicting Postoperative 1-Year Mortality.

Authors:  Tak Kyu Oh; Jaebong Lee; Jung-Won Hwang; Sang-Hwan Do; Young-Tae Jeon; Jin Hee Kim; Kooknam Kim; In-Ae Song
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.